Investor confidence, reflected in a high P/S ratio and increasing share prices despite fluctuations, suggests anticipated persistent growth in Phreesia. Caution advised over sole reliance on price-to-sales ratios for investment decisions.
Gainers: •$オクタ(OKTA.US)$+15.8% (In reaction to earnings) •$ストーン(STNE.US)$+12.9% (In reaction to earnings) •$ターニング・ポイント・セラピューティクス(TPTX.US)$+116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025) •$アミリックス・ファーマシューティカルズ(AMLX.US)$+24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
Gainers: •$クロビス・オンコロジー(CLVS.US)$+40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial) •$デア・バイオサイエンス(DARE.US)$+13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO) •$クーラー・テクノロジー・グループ(KULR.US)$+9.5% (secured a battery sa...
フリージアに関するコメント
コラムToday's pre-market stock movers: TSLA, CHGG, OKTA, TPTX and more
• $オクタ(OKTA.US)$ +15.8% (In reaction to earnings)
• $ストーン(STNE.US)$ +12.9% (In reaction to earnings)
• $ターニング・ポイント・セラピューティクス(TPTX.US)$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $アミリックス・ファーマシューティカルズ(AMLX.US)$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
コラムTop upgrades and downgrades on 4/14
• $CDW(CDW.US)$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $コルテバ(CTVA.US)$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $コレクションズ・コーポレーション・オブ・アメリカ(CXW.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $デルタ航空(DAL.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B.フラー(FUL.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $ハンティントン・インガルス・インダストリーズ(HII.US)$ : Cowen U...
コラムToday's pre-market stock movers: CLVS, PATH, DARE and more
• $クロビス・オンコロジー(CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $デア・バイオサイエンス(DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $クーラー・テクノロジー・グループ(KULR.US)$ +9.5% (secured a battery sa...
まだコメントはありません